Lumida
/SRRK
⌘K
Scholar Rock Holding Corp

Scholar Rock Holding Corp

SRRK
$55.41USD-0.47%-0.26 today

MARKET CAP

6.7B

P/E (TTM)

FWD P/E

DAY RANGE

$55 – $57

52W RANGE

$27
$62

AI Summary

Stalk
StalkMedium

SRRK remains in a Stage 2 advancing uptrend with rising EMAs but shows a Bullish Exhaustion candle at recent highs. The current pullback into the rising 9-, 20-, and 50-day EMAs suggests waning momentum. Under a speculative framework, entries should be deferred until clear acceptance or resilience at these dynamic support levels emerges.

  • FDA accepted BLA with PDUFA on Sep 30, 2026; two fill-finish sites ready.
  • Q1 2026 cash balance of $480M (plus $100M debt drawdown, $98M ATM) fuels launch.
  • Q1 2026 OPEX of $102M (high stock-based comp) underscores weak profitability factors.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2019FY 2020FY 2021FY 2022TREND
Sales, Adj.$20.5M$15.4M$18.8M$33.2M
YoY %-24.8%+22.2%+76.4%
P / Sales17.7x96.8x48.5x17.2x
EV / Sales20.0x94.7x44.2x17.0x
Gross Profit, Adj.$20.5M$15.4M$18.8M$33.2M
YoY %-24.8%+22.2%+76.4%
Margin %100.0%100.0%100.0%100.0%
EV / Gross Profit20.0x94.7x44.2x17.0x
EBITDA, Adj.$-53.2M$-85.4M$-127.3M$-124.5M
YoY %-6.7%-60.4%-49.1%+2.2%
Margin %-259.8%-554.4%-676.5%-375.0%
EV / EBITDA-7.7x-17.1x-6.5x-4.5x
EBIT$-54.5M$-86.9M$-129.9M$-134.4M
YoY %-7.6%-59.3%-49.5%-3.4%
Margin %-266.2%-564.0%-690.5%-404.8%
EV / EBIT-7.5x-16.8x-6.4x-4.2x
Net Income$-51.0M$-86.5M$-131.8M$-134.5M
YoY %-3.4%-69.6%-52.4%-2.1%
Net Margin-248.9%-561.5%-700.5%-405.2%
EPS (GAAP)-$1.85-$2.81-$3.59-$2.26
YoY %+41.3%-51.9%-27.8%+37.0%